R-Team Biomed is seeking strategic partnerships and investment to accelerate Efixan Platform commercialization and global reach.

By investing in R-Team, you support production scaling, regulatory approvals, and market entry into a $74.4 billion veterinary market with significant growth potential.

Our proven technology, established IP, and expedited regulatory strategy make Efixan a compelling opportunity for partners experienced in veterinary markets.

Together, we can address critical unmet needs in equine dermatology and improve health outcomes for horses worldwide.